Dr. Herzog is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2139 Auburn Ave
Cincinnati, OH 45219Phone+1 513-585-2323Fax+1 513-585-4893
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Gynecologic Oncology, 1990 - 1993
- TriHealth (Bethesda North and Good Samaritan Hospitals)Residency, Obstetrics and Gynecology, 1986 - 1990
- University of Cincinnati College of MedicineClass of 1986
Certifications & Licensure
- OH State Medical License 1988 - 2026
- NY State Medical License 2004 - 2015
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- New York Magazine: Top Doctors Castle Connolly, 2007-2014
- Top Doctors: New York Metro Area Castle Connolly, 2007-2013
- Join now to see all
Publications & Presentations
PubMed
- Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies.Gabriel Levin, Bradley J Monk, Bhavana Pothuri, Robert Coleman, Thomas Herzog
American Journal of Obstetrics and Gynecology. 2025-01-23 - Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.Michael D Toboni, Kaitlyn Dinkins, Sharon Wu, Tyler Mattox, Matthew J Oberley
Gynecologic Oncology. 2025-01-20 - Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial can...Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak
International Journal of Gynecological Cancer. 2025-01-06
Other
- Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-f
UpToDate, Wolters Kluwer Health - 2012-11-13 - First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancerHerzog TJ
http://www.uptodate.com/contents/first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ova
UpToDate, Wolters Kluwer Health - 2013-04-08
Press Mentions
- Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 9th, 2023
- Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s CancerFebruary 24th, 2022
- Combo Tx Active in Recurrent, Platinum-Resistant Ovarian CancerMarch 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: